Antiplatelet strategy in primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: A perspective from the guideline appraisal.
Menghui LiuXiaodong ZhuangXiaohong ChenShaozhao ZhangDaya YangXiangbin ZhongZhenyu XiongYifen LinHuimin ZhouYongqiang FanPeihan XieYiquan HuangLichun WangXinxue LiaoPublished in: Journal of diabetes investigation (2020)
Physicians should use the recommendations from "strongly recommended" guidelines to make informed decisions and know the consensuses of current guidelines. Dual antiplatelet therapy should be used within 12 months when type 2 diabetes patients experience acute coronary syndrome and/or percutaneous coronary intervention/coronary artery bypass grafting, with subsequent long-term aspirin use. In primary prevention, aspirin should not be routinely used by individuals with type 2 diabetes, but might be considered for those with high CVD risk.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- coronary artery bypass grafting
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- type diabetes
- cardiovascular disease
- coronary artery bypass
- end stage renal disease
- newly diagnosed
- atrial fibrillation
- primary care
- prognostic factors
- cardiovascular events
- clinical practice
- cardiovascular risk factors
- left ventricular
- heart failure